6:11 PM
 | 
Sep 06, 2012
 |  BC Extra  |  Top Story

Merck KGaA, Symphogen in cancer deal

Symphogen A/S (Copenhagen, Denmark) granted Merck KGaA (Xetra:MRK) exclusive, worldwide rights to develop and commercialize cancer product Sym004. Symphogen will receive EUR 20 million ($25.2 million) up front and is eligible for up to EUR 475 million ($597.4...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >